EVALUATION OF THE TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Costa CA, Ferrer CS, Ramirez LG, Arranz EM, et al. Gastroenterol Hepatol 2024 May 7:502201. doi: 10.1016/j.gastrohep.2024.502201.

Read + Share

Amedeo Smart

Independent Medical Education

Costa CA, Ferrer CS, Ramirez LG, Arranz EM, et al. EVALUATION OF THE TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Gastroenterol Hepatol 2024 May 7:502201. doi: 10.1016/j.gastrohep.2024.502201.
PMID: 38723766